NASDAQ · Biotechnology

Cyteir Therapeutics, Inc. (CYT) Stock

$3.02 -2.27% NASDAQ: CYT Healthcare

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines.

Valuation

MetricValue
Price$3.02
Market Cap$108.71M
P/E Ratio-2.42
P/B Ratio0.73
P/S Ratio0.00
EPS (TTM)$-1.25
52-Week High$3.19
52-Week Low$1.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-26.35%
ROA-28.68%
ROCE-32.57%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio28.07

Annual Financials (USD)

Metric2019202020212022
Revenue$0$0$0$0
Operating Profit$-16.0M$-21.0M$-42.0M$-48.0M
Net Profit$-15.0M$-21.0M$-42.0M$-44.0M
EPS$-0.77$-0.87$-1.18$-1.25
Op Margin-201312.5%———

Balance Sheet (USD)

Metric2019202020212022
Total Assets$31.0M$14.0M$195.0M$153.0M
Total Liabilities$60.0M$62.0M$8.0M$7.0M
Cash$29.0M$11.0M$190.0M$147.0M
Borrowings$0$0$0$1.0M

Latest News

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights PR Newswire · Jul 20, 2026 CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why Zacks · Jul 8, 2026 OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA Zacks Small Cap Research · Jul 8, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026 Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th GlobeNewswire · Jun 23, 2026

Cash Flow (USD)

Metric2019202020212022
Operating Cash Flow$-18.0M$-19.0M$-36.0M$-43.0M
Investing Cash Flow$0$-2.0M$-2.0M$-1.0M
Financing Cash Flow$37.0M$1.0M$216.0M$0
Net Cash Flow$19.0M$-18.0M$179.0M$-43.0M
Free Cash Flow$-18.0M$-19.0M$-37.0M$-43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.05
EV / EBITDA0.81
FCF Yield-39.41%
Quick Ratio28.07
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AADIAadi Bioscience, Inc. $2.05 -2.38% -1.49 $94.89M 0.00%
DBTXDecibel Therapeutics, Inc. $4.91 -0.81% -1.95 $123.37M 0.00%
GRAYGraybug Vision, Inc. $5.50 -10.80% -4.23 $120.98M 0.00%
HLVXHilleVax, Inc. $2.09 -0.48% -9.09 $104.76M 0.00%
JNCEJounce Therapeutics, Inc. $1.88 +0.00% -1.90 $98.95M 0.00%

About Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.

Cyteir Therapeutics, Inc. is headquartered in US.

Cyteir Therapeutics, Inc. (CYT) stock trades at $3.02 with a market capitalization of $108.71M. The stock is valued at a price-to-earnings (P/E) ratio of -2.42, price-to-book of 0.73, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.65 and $3.19, and currently trades 5.3% below its 52-week high.

On profitability, Cyteir Therapeutics, Inc. generates a return on equity (ROE) of -26.35%, return on capital employed of -32.57%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: cyteir.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides